Abstract：Objective To investigate the clinical and pathological features of patients with proliferative and sclerosing IgA nephropathy. Methods Retrospective analysis was performed on 116 patients with proliferative and sclerosing IgA nephropathy confirmed by renal biopsy in Department of Nephropathy, Xiyuan Hospital, China Academy of Chinese Medical Sciences from January 2015 to March 2019. According to chronic kidney diseases (CKD) stage, they were divided into CKD stage 1-5. The 24 h urinary protein quantification and comorbidities of each group were compared (including the presence or absence of hypertension, hyperuricemia, etc.). They were divided into group with ischemic kidney injury and group without ischemic kidney injury according to the presence or absence of ischemic kidney injury, and they were divided into group with IgM deposition and group without IgM deposition according to the presence or absence of IgM deposition group. The 24 h urinary protein quantification, serum creatinine level and estimated glomerular filtration rate (eGFR) of each group were compared. Results There were statistically significant differences among the five groups in age, 24 h urine protein quantification, and proportion of hyperuricemia, pharyngitis and tonsillitis (all P < 0.05). The serum creatinine and proportion of hypertension in group with ischemic kidney injury were higher than those of the group without ischemic kidney injury, and eGFR was lower than that of the group without ischemic kidney injury, with statistically significant differences (all P < 0.05). The age and eGFR level of group with IgM deposition were lower than those of group without IgM deposition, the serum creatinine level was higher than that of group without IgM deposition, and the differences were statistically significant (all P < 0.05). Conclusion The clinical and pathological lesions in patients with proliferation and sclerosing IgA nephropathy are severe, and 24 h urine protein quantitative, blood creatinine, ischemic kidney injury and IgM deposition may be risk factors for renal progression and poor renal prognosis.
常美莹 张昱. 116例增生硬化性IgA肾病患者的临床及病理特点分析[J]. 中国医药导报, 2020, 17(28): 96-99.
CHANG Meiying ZHANG Yu. Clinical and pathological features of 116 patients with proliferative and sclerosing IgA nephropathy. 中国医药导报, 2020, 17(28): 96-99.
[1] 刘刚，马序竹，邹万忠，等.肾活检患者肾脏病构成十年对比分析[J].临床内科杂志，2004，21（12）：834-838.
[2] Maixnerova D，Reily C，Bian Q，et al. Markers for the progression of IgA nephropathy [J]. J Nephrol，2016，29（4）：535-541.
[3] Shu D，Xu F，Su Z，et al. Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years：a case-control study [J]. BMC Nephrol，2017，18（1）：11.
[4] Moriyama T，Tanaka K，Iwasaki C，et al. Prognosis in IgA nephropathy：30-year analysis of 1，012 patients at a single center in Japan [J]. PLoS One，2014，9（3）：e91756．
[5] National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease：e-valuation，classification，and stratification [J]. Am J Kidney Dis，2002，39（2 Suppl 1）：S1-S266.
[6] 全国肾活检病理诊断研讨会.肾活检病理诊断指导意见[J].中华肾脏病杂志，2001，17（4）：270-275.
[7] Min L，Wang Q，Cao L，et al. Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy [J]. Oncotarget，2017，8（29）：48375-48384.
[8] Zheng Y，Wang Y，Liu S，et al. Potential Blood Pressure Goals in IgA Nephropathy：Prevalence，Awareness，and Treatment Rates in Chronic Kidney Disease Among Patients with Hypertension in China（PATRIOTIC）Study [J]. Kidney Blood Press Res，2018，43（6）：1786-1795.
[9] Tomino Y. Immunopathological predictors of prognosis in IgA nephropathy [J]. Contrib Nephrol，2013，181：65-74．
[10] 周悦玲，蒋更如.IgA肾病进展至终末期肾病临床预测的研究现状[J].上海交通大学学报：医学版，2016，36（2）：296-301.
[11] 马明明，管保章，罗丽花，等.50例增生硬化性IgA肾病的临床病理特点及激素治疗疗效分析[J].中华肾脏病杂志，2016，32（8）：568-572.
[12] 程根阳，王云，袁文明，等.增生硬化性IgA肾病伴贫血患者的临床病理特征及预后[J].中国全科医学杂志，2018， 21（18）：2185-2189.
[13] 何玲艳，曹霞，杨淡昳，等.单纯血尿和/或轻度蛋白尿IgA肾病临床病理分析[J].中南大学学报：医学版，2019， 44（6）：642-648.
[14] 段姝伟，张岩，吴杰，等.少量蛋白尿IgA肾病患者镜下血尿与病理指标的相关性分析[J].中华肾病研究电子杂志，2018，7（3）：102-106.
[15] 廖莹，万启军，胡豪飞，等.单纯性血尿IgA肾病临床病理回顾性分析[J].深圳中西医结合杂志，2017，27（9）：31-33.
[16] 刘扬，刘睿，杨再波，等.IgA肾病单纯性血尿患者牛津病理分型特点及临床预后分析[J].中国中西医结合肾病杂志，2019，20（6）：498-500.
[17] 刘欢欢，尹良红，刘璠娜，等.IgA肾病单纯性血尿患者肾脏病理分级与临床的关系[J].临床医学工程，2017，S1：23-27.
[18] 刘杰，杨定平.少量蛋白尿IgA肾病临床特征及肾功能损伤相关因素分析[J].临床肾脏病杂志，2018，18（4）：206-210.
[19] Berthoux F，Mohey H，Laurent B，et al. Predicting the risk for dialysis or death in IgA nephropathy [J]. J Am Soc Nephrol，2011，22（4）：752-761．
[20] 吕天洋，张静，贾红彦，等.原发性IgA肾病并发血尿酸升高患者影响因素分析[J].中国实验诊断学，2019，23（9）：1536-1537．
[21] 程根阳，李茹曼，李海剑，等.IgA肾病合并高尿酸血症患者血清TIMP-1水平与肾脏病理分型的关系[J].河南医学研究，2018，27（10）：1763-1765.
[22] Cheng GY，Liu DW，Zhang N，et al. Clinical and prognostic implications of serum uric acid levels on IgA nephropathy：a cohort study of 348 cases with a mean 5-year follow-up [J]. Clin Nephrol，2013，80（1）：40-46.
[23] 邹万忠.肾活检病理学[M].3版.北京：北京大学医学出版社，2014：126-133.
[24] Liu Z，Li L. Polymorphism in IgA nephropathy [J]. Nephrology，2015，3（1）：63-66.
[25] Yin XL，Zou MS，Zhang Y，et al. Twenty-three-year review of disease patterns from renal biopsies：an experience from a pediatric renal center [J]. J Nephrol，2016， 26（4）：699-707.
[26] Knoppova B，Reily C，Maillard N，et al. The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy [J]. Front Immunol，2016，7：117.
[27] 王建，李庆士，李龙海，等.277例IgA肾病患者病理分型与临床特点分析[J].中国医学前沿杂志：电子版，2015， 7（8）：85-88.
[28] 豆利军，王国平，闵瘤芳，等.IgM沉积预测原发性IgA肾病患者预后风险性及相关危险因素分析[J].现代中西医结合杂志，2019，28（28）：3144-3148.
2020, Vol. 17 
京公网安备 11010502046598号